Floatz logo

L-Carnitine L-Tartrate

Chemotherapeutic Agent Toxicity

HealthPartners InstitutePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

66 Active assets in the Chemotherapeutic Agent Toxicity cohort.

Asset / SponsorPhaseRating
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
HR20013
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3BB
Netupitant
Instituto Brasileiro de Controle do Cancer
Phase 3BB

View all 50 →

Same molecule, other indications

L-Carnitine L-Tartrate is also rated in:

toxic encephalopathyDormant
B
Indicative ·
60 / 100
View asset →
Non-alcoholic Fatty Liver Disease (NAFLD)Dormant
CCC
Indicative ·
55 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →